Reduced cognitive ability in people with rheumatoid arthritis compared with age-matched healthy controls by Gwinnutt, James M. et al.
Concise report
Reduced cognitive ability in people with rheumatoid
arthritis compared with age-matched healthy
controls
James M. Gwinnutt 1, Task Toyoda2, Stephen Jeffs2, Emma Flanagan2,
Jacqueline R. Chipping2,3, Jack R. Dainty2, Eneida Mioshi4,
Michael Hornberger2 and Alex MacGregor 2,3
Abstract
Objective. The aim was to compare the cognitive ability of people with RA with healthy controls (HCs).
Methods. People with RA were recruited from the Norfolk Arthritis Register (NOAR), a population-based
cohort study of people with inflammatory arthritis. Data on aged-matched HCs (people with no cognitive im-
pairment) came from the comparison arm of The Dementia Research and Care Clinic Study (TRACC). People
with RA and HCs performed a range of cognitive ability tasks to assess attention, memory, verbal fluency,
language, visuospatial skills, emotional recognition, executive function and theory of mind. A score of <88 on
the Addenbrooke’s Cognitive Examination III was considered cognitive impairment. Scores were compared
using linear regression adjusting for age, sex, smoking status, education, BMI, anxiety and depression.
Results. Thirty-eight people with RA [mean (S.D.) age: 69.1 (8.0) years; 25 (65.8%) women] were
matched with 28 HCs [mean (S.D.) age: 68.2 (6.4) years; 15 (53.6%) women]. Twenty-three (60.5%)
people with RA were considered to have mild cognitive impairment [mean (S.D.) Addenbrooke’s
Cognitive Examination III: RA ¼ 85.2 (7.4), HC ¼ 96.0 (2.5)]. People with RA had impairments in mem-
ory, verbal fluency, visuospatial functioning, executive function and emotional recognition in faces com-
pared with HCs, after adjustment for confounders.
Conclusion. People with RA had cognitive impairments in a range of domains. People with RA might
benefit from cognitive impairment screening to allow for early administration of appropriate interventions.
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Introduction
RA is a chronic inflammatory condition that results in
swollen joints, pain and functional disability. RA is as-
sociated with increased risk of other conditions, with
some evidence suggesting an association between
RA and increased risk of dementia [1], but evidence
is conflicting [2]. This may be attributable to con-
founding factors such as smoking, education and
medication [3].
Key messages
. In this study, 60.5% of the people with RA had cognitive impairment.
. People with RA had impairments in memory, verbal fluency, executive function and emotional recognition.
. People with RA may require cognitive impairment screening, given the negative consequence on daily life.
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A precursor to dementia is mild cognitive impairment
(MCI), involving memory and cognitive difficulties that
have not developed into a loss of independence. People
with MCI suffer from reduced quality of life [4], reduced
functional ability [5] and lower adherence to treatment
for other conditions [6]. Evidence suggests that some
people with RA might have MCI, because they experi-
ence difficulties compared with controls in certain
aspects of cognition, such as verbal function, memory
and attention [7]. Potential drivers of cognitive impair-
ment in RA could operate through the relationship be-
tween RA and cardiovascular disease (itself known to
be a predictor of cognitive impairment) [8], an increased
occurrence of CNS-related autoantibodies [9], or the in-
fluence of depression or anti-rheumatic medication [7].
However, previous studies have been hampered by rela-
tively small sample sizes, inconsistent management of
confounding variables and limited range of cognitive
domains assessed. Any screening for MCI may need the
administration of a large battery of cognitive tests, but
at present it is unclear whether administration of such a
battery is feasible or necessary.
Therefore, the objectives of this study were to assess
the value and feasibility of conducting a range of tests
that assess different cognitive domains in people with
RA, and to examine whether people with RA exhibit a
specific pattern of cognitive impairment compared with
healthy controls (HC), after taking into account important
confounding factors.
Methods
The Norfolk Arthritis Register (NOAR) is a prospective in-
ception cohort of people with inflammatory arthritis (and
its subset, RA), situated in Norfolk, UK [10]. Recruitment
began in 1990, and the inclusion criteria are at least two
swollen joints for 4 weeks. For the present study, we
identified from the NOAR database prospective partici-
pants who met the following criteria: (i) age 54 years;
(ii) RA according to the 2010 ACR/EULAR criteria [11];
(iii) symptom duration 1 year; and (iv) no known cogni-
tive impairment, neurological or neurodegenerative dis-
ease (such as dementia). These NOAR participants were
invited to take part in the study.
Control data came from The Dementia Research and
Care Clinic Study (TRACC). TRACC is a transdiagnostic
study aiming to recruit and follow longitudinally partici-
pants from Norfolk and the neighbouring county of
Suffolk with a range of diagnoses (Alzheimer’s disease,
MCI, motor neuron disease and Pick’s disease complex)
in addition to a cohort of HCs for comparison.
Participants were eligible to take part in the HC sample
of TRACC if they were: (i) aged between 50 and
75 years; (ii) scored >88 on the Addenbrooke’s
Cognitive Examination III (ACE-III; see below for descrip-
tion); and (iii) were not diagnosed with dementia or a
current mental health disorder. Furthermore, to be in-
cluded as controls in the present study, participants had
to have no diagnosis of RA and have completed the
same cognitive assessments as the NOAR participants.
Both NOAR and TRACC received ethical approval
(NOAR: 15/EE/0076; TRACC: 16/LO/1366), and all par-
ticipants provided written informed consent.
Cognitive assessments
People with RA and HCs underwent a series of cognitive
assessments aiming to assess a range of different cog-
nitive domains. For all scales, higher scores indicate
better cognitive function.
. The Addenbrooke’s Cognitive Examination III (ACE-III):
cognitive tests assessing five cognitive domains,
namely attention, memory, verbal fluency, language
and visuospatial skills [12]. A total score of <88 indi-
cates cognitive impairment [13].
. Institute of Cognitive Neurology Frontal Screening (IFS):
measure of executive function [14].
. Mini Social Cognition and Emotion Assessment (mini-
SEA): faux-pas understanding (theory of mind test) and
facial emotional recognition [15].
. Rey Complex Figure Test (RCFT): assessment of visuo-
spatial function, in which participants copy abstract
images before later drawing from memory [16].
The participants with RA also completed a feedback
form regarding the acceptability of the cognitive tests.
Covariates
Age, sex, smoking status (current, former or never) and
education level [no qualifications, GCSEs or O levels
(qualifications at 16 years in the UK), A levels (qualifica-
tions at 18 years in the UK) and/or degree] were self-
reported by all participants. Height and weight were
measured by research staff at assessments, and BMI (in
kilograms per square metre) was calculated. Anxiety and
depression severity were assessed by the Generalized
Anxiety Disorder-7 (GAD-7) [17] and the Patient Health
Questionnaire-9 (PHQ-9) [18], respectively.
Statistical analysis
HCs from TRACC were age matched with the NOAR
participants. Demographics, cognitive assessments and
feedback were summarized using descriptive statistics,
stratified by RA/HC status. Differences in characteristics
between people with RA and HCs were assessed using
Student’s unpaired t-tests or v2 tests, depending on the
data. Differences in the cognitive assessment scores be-
tween the people with RA and controls were assessed
using linear regression, controlling for age, sex, BMI,
smoking status, education, anxiety and depression.
Given that each cognitive assessment has a different
scale, to aid comparability the cognitive assessments
were also standardized, and the standardized scores
were compared between groups using linear regression
(controlling for the same covariates). These standardized
mean differences (SMDs) represent the mean difference
in standard deviations of the assessment between peo-
ple with RA and controls. Mean and median substitution
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was used to impute missing data. Analyses were per-
formed using Stata v.14 (StatCorp, College Station, TX,
USA).
Patient and public involvement
Three patient partners were involved in the design of the
study and piloted the assessments to check the accept-
ability and feasibility for future participants.
Results
In total, 38 people with RA were recruited to this study
[mean age ¼ 69.1 (S.D.) 8.0] years, 25 (65.8%) women,
mean symptom duration ¼ 9.8 (S.D. 6.3) years]. These
people with RA were matched with 28 HCs from
TRACC. There were more women, people of higher BMI,
people with lower education and smokers in the RA
group compared with the controls. Furthermore, the
people with RA had significantly higher anxiety and de-
pression scores compared with the controls (Table 1).
The cognitive assessment battery was acceptable for
the people with RA, taking between 90 and 120 min to
complete. One hundred per cent of the people with RA
either agreed or strongly agreed that the time available
to complete the tests was about right, and 89% agreed
or strongly agreed that the amount of paperwork was
about right.
People with RA had poorer function on many of the
cognitive ability assessments compared with HCs after
confounding adjustment, including memory, verbal flu-
ency, language, visuospatial processing (ACE-III), execu-
tive function (IFS) and emotional recognition from faces
(Mini-SEA) (Table 2). In total, 23 (60.5%) people with RA
scored <88 on the total score of the ACE-III, indicating
cognitive impairment (compared with 0 HCs, because
this was an inclusion criterion for the HC group). There
were no significant differences between people with RA
and HCs in terms of attention (ACE-III), theory of mind
(faux-pas test from Mini-SEA) and visuospatial function-
ing when measured with the RCFT. When assessing the
standardized scores, the largest impairments in cogni-
tive ability between people with RA and controls were
seen in the memory and visuospatial components of the
ACE-III (memory SMD 0.8, 95% CI 1.2, 0.4; visuo-
spatial SMD 1.0, 95% CI 1.5, 0.5) and in executive
function (IFS; SMD 1.1, 95% CI 1.5, 0.7).
Discussion
This study demonstrates that performing cognitive test
batteries is feasible for people with RA, and these par-
ticular assessments are acceptable to participants (e.g.
ACE-III; judged based on the participant evaluation).
Furthermore, there is a clear signature of reduced cogni-
tive ability in this group compared with controls. In total,
60.5% of the people with RA scored below the ACE-III
cut-off, indicating cognitive impairment. When investi-
gating the individual dimensions, people with RA had
impaired memory, verbal fluency, executive function and
emotional recognition compared with HCs. This was in-
dependent of confounding factors such as age, anxiety,
depression, education and body mass. People with RA
had impaired visuospatial functioning compared with
HCs as measured by the ACE-III, but not with the RCFT.
This could be attributable to differences in difficulty of
the tasks, whereby the ACE-III contains a free-recall ele-
ment (clock drawing), whereas the RCFT involves copy-
ing (and later recalling) a pre-specified abstract design.
TABLE 1 Demographic characteristics of the people with RA and healthy controls
Variable People with RA Healthy controls P-value
n 38 28
Age, mean (S.D.), years 69.1 (8.0) 68.2 (6.4) 0.64a
Female, n (%) 25 (65.8) 15 (53.6) 0.32b
Symptom duration, mean (S.D.), years 9.8 (6.3) – –
BMI, mean (S.D.), kg/m2 28.3 (5.7) 24.1 (4.4) 0.002a
Education, n (%)
No qualifications 17 (44.7) 5 (17.9) 0.07b
GCSEs/O levels 6 (15.8) 7 (25.0)
A levels and/or degree 15 (39.5) 16 (57.1)
Smoking status, n (%)
Never 17 (44.7) 18 (64.3) 0.12b
Former 14 (36.8) 9 (32.1)
Current 7 (18.4) 1 (3.6)
Depression mean (S.D.), (PHQ-9, range: 0–27c) 6.0 (6.7) 1.1 (1.8) 0.0004a
Anxiety mean (S.D.), (GAD-7, range: 0–21c) 4.9 (5.5) 0.6 (1.3) 0.0001a
aStudent’s unpaired t-test. bv2 test. cHigher scores indicate worse depression/anxiety. GAD-7¼Generalised Anxiety
Disorder-7; GCSE ¼ General Certificate of Secondary Education; PHQ-9¼Patient Health Questionnaire-9.
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Lastly, there were no differences between the groups in
terms of attention and theory of mind.
A systematic review of studies using the ACE reported
a cut-point of <88 for cognitive impairment, indicating
that a majority of people (60.5%) with RA in this cohort
have some cognitive impairment [13]. This is higher than
found in some previous studies (e.g. Shin et al. [8]:
31%; Appenzeller et al. [19]: 30%) but in line with others
(e.g. Vitturi et al. [20]: 72.4%), although these other stud-
ies used different criteria for cognitive impairment, indi-
cating the need for an agreed definition of cognitive
impairment in RA [8, 19, 20]. This high prevalence of
people with RA scoring <88 on the ACE-III (indicating
cognitive impairment) is important because many people
with MCI later develop dementia: in one study, 59% of
54 people with multi-domain MCI later developed de-
mentia [21]. This finding, alongside studies indicating
that RA is a risk factor for dementia [1], indicates the
need for MCI and dementia screening in RA. In this way,
early interventions with the potential to reduce future de-
mentia risk can be instituted, in addition to support for
patients and families in daily management when demen-
tia is present. The specific areas of cognitive impairment
in RA shown in the present study (memory, verbal flu-
ency, executive function and emotional recognition)
have been reported in RA in other settings, summarized
in a recent systematic review [7]. Furthermore, emerging
evidence of a similar pattern of cognitive impairment in
other rheumatic diseases has been reported [22, 23].
Our findings suggest that targeted cognitive screening
is potentially needed as part of routine practice to detect
clinically relevant cognitive changes in RA and other in-
flammatory diseases. In a clinical setting, it is noteworthy
that cognitive assessments could be delivered remotely,
which might be an important component of the future
management of people with rheumatic diseases. These
findings also highlight the need for a more detailed un-
derstanding of the risk factors leading to cognitive impair-
ment in this group, in order to guide strategies for
prevention and treatment. This includes, for example, the
contribution of exposure to anti-inflammatory drug treat-
ments, lifestyle factors (e.g. diet, smoking and alcohol)
and related conditions, including pain, anxiety and de-
pression. Furthermore, future research should address
the relative contributions of physical and cognitive factors
to functional ability in RA [20, 24].
Our study has a number of strengths. We have exam-
ined a large array of cognitive assessments. The study
was nested in a population-based cohort, allowing the
selection of representative cases of RA. However, our
participants were volunteers, and it is possible that con-
cern over their cognitive ability might have motivated
them to take part. No additional clinical or laboratory
testing was performed as part of this study to investigate
changes in cognition further. Furthermore, the ACE cut-
off for MCI defines cognitive impairment associated with
increased risk of dementia, and people below this thresh-
old might require further assessment and monitoring [13].
Given that RA is thought to be a risk factor for dementia,
perhaps a less severe cut-off should be used when
screening this group, which could be addressed in future
research. We excluded younger people with RA
(<54 years) in order to maximize the power to detect
cognitive impairment in RA. However, this means that the
results are not generalizable to younger people with RA.
The limited sample size meant that we could not test the
association between clinical factors (e.g. co-morbidities,
medications) and cognitive impairment in RA.














Total (0–100) 85.2 (7.4) 96.0 (2.5) 7.0 (9.6, 4.4) 0.9 (1.2, 0.6) <0.0001
Attention (0–18) 16.5 (1.9) 17.7 (0.5) 0.0 (0.7, 0.7) 0.0 (0.4, 0.4) 0.952
Memory (0–26) 19.8 (4.0) 24.8 (1.6) 3.3 (5.0, 1.5) 0.8 (1.2, 0.4) <0.0001
Verbal fluency (0–14) 9.9 (2.6) 12.1 (1.3) 1.7 (2.9, 0.5) 0.7 (1.2, 0.2) 0.007
Language (0–26) 24.6 (1.7) 25.6 (0.6) 0.7 (1.5, 0.01) 0.5 (1.0, 0.01) 0.047
Visuospatial (0–16) 14.4 (1.5) 15.8 (0.5) 1.3 (2.0, 0.6) 1.0 (1.5, 0.5) <0.0001
IFS (0–30) 20.4 (3.4) 25.3 (2.0) 4.1 (5.7, 2.6) 1.1 (1.5, 0.7) <0.0001
Mini-SEA
Facial recognition (0–15) 10.3 (1.1) 11.2 (0.9) 0.8 (1.3, 0.2) 0.7 (1.2, 0.2) 0.005
Faux-pas (0–15) 14.2 (1.2) 14.0 (1.2) 0.4 (0.3, 1.1) 0.3 (0.2, 0.9) 0.232
RCFT
Copy (0–36) 30.2 (5.1) 33.3 (2.9) 1.3 (3.8, 1.1) 0.3 (0.8, 0.2) 0.277
Recall (0–36) 15.2 (7.9) 18.1 (5.3) 0.8 (4.9, 3.3) 0.1 (0.7, 0.5) 0.711
aHigher scores indicate better function. bMean difference from linear regression, controlling for age, sex, BMI, smoking status,
education level, depression (PHQ-9) and anxiety (GAD-7). cEach cognitive variable is standardized; the coefficients represent
the number of standard deviations difference between people with RA and controls, adjusted for the same confounders above.
ACE-III ¼ Addenbrooke’s Cognitive Examination III; GAD-7¼Generalised Anxiety Disorder-7; IFS ¼ Institute of Cognitive
Neurology Frontal Screening; Mini-SEA ¼ Mini Social Cognition and Emotion Assessment; PHQ-9¼Patient Health
Questionnaire-9; RCFT ¼ Rey Complex Figure Test; SMD ¼ standardized mean difference.
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In conclusion, this study shows that people with RA
have lower cognitive ability across a range of domains
compared with HCs. Given the large detrimental effect
that cognitive impairment can have on function and
quality of life and the feasibility and acceptability of per-
forming cognitive assessments for people with RA,
screening of cognitive ability might be warranted in this
clinical group.
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INECO Frontal Screening (IFS): a brief, sensitive, and
specific tool to assess executive functions in dementia. J
Int Neuropsychol Soc 2009;15:777–86.
15 Bertoux M, Delavest M, de Souza LC et al. Social
Cognition and Emotional Assessment differentiates
frontotemporal dementia from depression. J Neurol
Neurosurg Psychiatry 2012;83:411–6.
16 Meyers JE, Meyers KR. Rey complex figure test under
four different administration procedures. Clin
Neuropsychol 1995;9:63–7.
17 Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief
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